U.S. FOOD AND DRUG ADMINISTRATION (FDA) CLEARS NOVEL IMAGESENSE(TM) TECHNOLOGY FOR USE WITH COLPOSCOPY
Precedent setting technology in Colposcopy, the current Gold Standard for detecting Cervical Cancer
San, Diego, CA., January 5, 2011 – STI Medical Systems, an industry leader in medical imaging systems and machine vision software, announced today that the U.S. Food and Drug Administration (FDA) has given clearance to the Company’s precedent-setting ImageSense™ technology for use in colposcopy. This new proprietary technology represents an entirely new way of presenting digital imagery in the doctor’s office, and is first-in-class for colposcopy. This represents an advance in colposcope system technology as colposcopes used in evaluating cervical neoplasia have remained largely unchanged for over 50 years.
Acetowhitening is one indicator currently used by doctors to identify areas of the cervix possibly containing disease. ImageSense is a tool for displaying areas of acetowhitening by producing a digital output depicting the color differences of the cervix before and after the application of acetic acid during a typical colposcopic exam. By digitizing and memorializing an otherwise transient effect and enabling on-demand viewing of the acetowhite process, ImageSense displays information to the doctor in ways previously not possible.
ImageSense technology is currently in use on the Company’s UltraSightHD™ digital colposcopy system. The combined product offers a fully integrated clinical workflow solution for colposcopy that also incorporates DICOM-compatible imagery and a seamless Electronic Medical Records (EMR) interface via its onboard touch-screen user interface. ImageSense technology provides the UltraSightHD product with a unique competitive advantage over all other colposcopes in the market.